Jingjing Wang1, Yueying Wang1, Wubin Qian1, Jia Xue1, Sheng Guo1, Likun Zhang1, Henry Li2
1Crown Bioscience, Inc., San Diego, California, USA
2Hanx Biopharmaceuticals Inc., Oceanside, California, USA
Diffuse large B cell lymphoma (DLBCL), the largest subtype of non-Hodgkin’s lymphoma (NHL), ~40%, is a heterogeneous disease with diverse pathogenesis. Epstein-Barr Virus positive DLBCL (EBV+ DLBCL) has also been recognized as a distinct subtype by WHO, originated from clonal B cell lymphoid proliferation, likely driven by EBV infection, which results in viral oncoprotein-induced transformations. BTK plays an exclusive and vital role in B cell development, and ibrutinib is a first-in class, orally-administered, selective and covalent BTK inhibitor (BTKi), approved for treating several B cell lymphomas, including mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL), but not yet for DLBCL. With the complexity of clinical trials, patient-derived xenografts (PDXs) become an alternative and powerful experimental system to investigate heterogeneous molecular pathology, and their corresponding pharmacology of DLBCLs.